BTIG reiterates Buy rating on Haemonetics with $84 target

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

BTIG analyst Marie Thibault has reiterated a Buy rating for Haemonetics, maintaining a price target of $84.

powered bylight_fuzz_icon
44020909

*this image is generated using AI for illustrative purposes only.

BTIG analyst Marie Thibault has reiterated a Buy rating for Haemonetics, maintaining a price target of $84. The rating affirmation signals continued confidence in the company's stock performance potential.

Analyst Rating and Price Target

The research note from BTIG reinforces the positive outlook on Haemonetics. The $84 price target provides a specific benchmark for investors regarding the stock's valuation expectations.

Firm Analyst Rating Price Target
BTIG Marie Thibault Buy $84
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific catalysts does BTIG expect to drive Haemonetics' stock toward the $84 price target?

How might recent market trends in the medical technology sector impact Haemonetics' growth trajectory?

What are the potential risks or challenges that could hinder Haemonetics from achieving this bullish outlook?

like15
dislike

Mizuho and BTIG positive on Haemonetics targets

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Mizuho analyst Anthony Petrone maintained an Outperform rating for Haemonetics and raised the price target to $85 from $70. BTIG analyst Marie Thibault also expressed confidence, reiterating a Buy rating with a price target of $84.

powered bylight_fuzz_icon
43092034

*this image is generated using AI for illustrative purposes only.

Mizuho analyst Anthony Petrone has maintained an Outperform rating for Haemonetics and increased the stock's price target to $85 from $70, reflecting a more optimistic outlook on the company's performance potential. Separately, BTIG analyst Marie Thibault has reiterated a Buy rating on Haemonetics with a price target of $84.

Rating and Target Details

The adjustments come as firms evaluate Haemonetics' position in the market. Mizuho's new price target of $85 represents a significant increase from the previous $70 level, while BTIG maintains its stance at $84.

Firm Analyst Rating Price Target
Mizuho Anthony Petrone Outperform $85
BTIG Marie Thibault Buy $84
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors are driving the increased optimism for Haemonetics' performance potential?

How might Haemonetics' market position evolve in response to these analyst upgrades?

What are the potential risks or challenges that could impact Haemonetics' ability to meet these higher price targets?

like17
dislike